Invasive pulmonary aspergillosis after COVID-19

Invasive aspergillosis is a disease that occurs mostly in people with a compromised immune system. The most important pathogen is Aspergillus fumigatus (it accounts for about 90% of the patients). The risk group includes patients who have primary and secondary immunodeficiencies, people receiving immunosuppressive therapy, cancer patients, etc. However, the incidence of this disease among COVID-19 ( COronaVIrus Disease 2019) patients have been reported recently. The aim of our work is to present a patient with invasive aspergillosis after COVID-19 who was not in a standard risk group and did not receive immunosuppressive therapy. Conclusion. Patients who had COVID-19 are under a risk of developing invasive pulmonary aspergillosis. Therefore, it is important to exclude this disease in a patient with prolonged pneumonia that does not respond to standard therapy.